NEWARK, N.J., April 19, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), (the “Company” or “AOB”), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter (“OTC”) products, today announced that four out of its five manufacturing subsidiaries are undergoing onsite short notice inspections directed by China State Food and Drug Administration (“SFDA”).
On 4/16/2012 China SFDA circulated an urgent notice nationwide calling for immediate suspension of sales and manufacturing of certain capsule products, sparked by the discovery of thirteen kinds of capsule products with origins from Qinghai and Changchun, etc. containing chrome far exceeding humanly tolerable limits .
SFDA directed onsite short notice inspections of a number of capsule manufacturers, including our following manufacturing subsidiaries: Guangxi Lingfeng Pharmaceutical (“GLP”), Boke Pharmaceutical (“Boke”), Harbin Three Happiness Pharmaceutical, and Changchun Xinan Pharmaceuticals (“CCXA”). Capsules are major product formulations for above subsidiaries.
The Company is cooperating in SFDA directed inspections, and GLP has passed the said capsule inspection as of this press release.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company’s filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
Contact: |
American Oriental Bioengineering, Inc. |
Kewa Luo |
(646) 367-1765 |
SOURCE American Oriental Bioengineering, Inc.
